• Something wrong with this record ?

Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis

K. Palumbo-Zerr, A. Soare, P. Zerr, A. Liebl, R. Mancuso, M. Tomcik, B. Sumova, C. Dees, CW. Chen, T. Wohlfahrt, T. Mallano, A. Distler, A. Ramming, K. Gelse, C. Mihai, O. Distler, G. Schett, JH. Distler,

. 2017 ; 76 (1) : 244-251. [pub] 20160425

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17024039

OBJECTIVES: TWIST1 is a member of the class B of basic helix-loop-helix transcription factors that regulates cell lineage determination and differentiation and has been implicated in epithelial-to-mesenchymal transition. Here, we aimed to investigate the role of TWIST1 for the activation of resident fibroblasts in systemic sclerosis (SSc). METHODS: The expression of Twist1 in fibroblasts was modulated by forced overexpression or siRNA-mediated knockdown. Interaction of Twist1, E12 and inhibitor Of differentiation (Id) was analysed by co-immunoprecipitation. The role of Twist1 in vivo was evaluated using inducible, conditional knockout mice with either ubiquitous or fibroblast-specific depletion of Twist1. Mice were either challenged with bleomycin or overexpressing a constitutively active transforming growth factor (TGF)β receptor I. RESULT: The expression of TWIST1 was increased in fibroblasts in fibrotic human and murine skin in a TGFβ/SMAD3-dependent manner. TWIST1 in turn enhanced TGFβ-induced fibroblast activation in a p38-dependent manner. The stimulatory effects of TWIST1 on resident fibroblasts were mediated by TWIST1 homodimers. TGFβ promotes the formation of TWIST1 homodimers by upregulation of TWIST1 and by induction of inhibitor of DNA-binding proteins, which have high affinity for E12/E47 and compete against TWIST1 for E12/E47 binding. Mice with selective depletion of Twist1 in fibroblasts are protected from experimental skin fibrosis in different murine models to a comparable degree as mice with ubiquitous depletion of Twist1. CONCLUSIONS: Our data identify TWIST1 as a central pro-fibrotic factor in SSc, which facilitates fibroblast activation by amplifying TGFβ signalling. Targeting of TWIST1 may thus be a novel approach to normalise aberrant TGFβ signalling in SSc.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17024039
003      
CZ-PrNML
005      
20170720123626.0
007      
ta
008      
170720s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/annrheumdis-2015-208470 $2 doi
035    __
$a (PubMed)27113414
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Palumbo-Zerr, Katrin $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
245    10
$a Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis / $c K. Palumbo-Zerr, A. Soare, P. Zerr, A. Liebl, R. Mancuso, M. Tomcik, B. Sumova, C. Dees, CW. Chen, T. Wohlfahrt, T. Mallano, A. Distler, A. Ramming, K. Gelse, C. Mihai, O. Distler, G. Schett, JH. Distler,
520    9_
$a OBJECTIVES: TWIST1 is a member of the class B of basic helix-loop-helix transcription factors that regulates cell lineage determination and differentiation and has been implicated in epithelial-to-mesenchymal transition. Here, we aimed to investigate the role of TWIST1 for the activation of resident fibroblasts in systemic sclerosis (SSc). METHODS: The expression of Twist1 in fibroblasts was modulated by forced overexpression or siRNA-mediated knockdown. Interaction of Twist1, E12 and inhibitor Of differentiation (Id) was analysed by co-immunoprecipitation. The role of Twist1 in vivo was evaluated using inducible, conditional knockout mice with either ubiquitous or fibroblast-specific depletion of Twist1. Mice were either challenged with bleomycin or overexpressing a constitutively active transforming growth factor (TGF)β receptor I. RESULT: The expression of TWIST1 was increased in fibroblasts in fibrotic human and murine skin in a TGFβ/SMAD3-dependent manner. TWIST1 in turn enhanced TGFβ-induced fibroblast activation in a p38-dependent manner. The stimulatory effects of TWIST1 on resident fibroblasts were mediated by TWIST1 homodimers. TGFβ promotes the formation of TWIST1 homodimers by upregulation of TWIST1 and by induction of inhibitor of DNA-binding proteins, which have high affinity for E12/E47 and compete against TWIST1 for E12/E47 binding. Mice with selective depletion of Twist1 in fibroblasts are protected from experimental skin fibrosis in different murine models to a comparable degree as mice with ubiquitous depletion of Twist1. CONCLUSIONS: Our data identify TWIST1 as a central pro-fibrotic factor in SSc, which facilitates fibroblast activation by amplifying TGFβ signalling. Targeting of TWIST1 may thus be a novel approach to normalise aberrant TGFβ signalling in SSc.
650    _2
$a zvířata $7 D000818
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblasty $x účinky léků $x metabolismus $7 D005347
650    _2
$a regulace genové exprese $x účinky léků $x fyziologie $7 D005786
650    _2
$a genový knockdown $7 D055785
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši knockoutované $7 D018345
650    _2
$a jaderné proteiny $x biosyntéza $x nedostatek $x genetika $x metabolismus $x fyziologie $7 D009687
650    _2
$a multimerizace proteinu $x fyziologie $7 D055503
650    _2
$a messenger RNA $x genetika $7 D012333
650    _2
$a malá interferující RNA $x genetika $7 D034741
650    _2
$a systémová sklerodermie $x metabolismus $x patologie $7 D012595
650    _2
$a signální transdukce $x fyziologie $7 D015398
650    _2
$a kůže $x patologie $7 D012867
650    _2
$a transformující růstový faktor beta $x farmakologie $7 D016212
650    _2
$a transkripční faktor Twist $x biosyntéza $x nedostatek $x genetika $x metabolismus $x fyziologie $7 D051879
655    _2
$a časopisecké články $7 D016428
700    1_
$a Soare, Alina $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany. Department of Internal Medicine and Rheumatology, Dr. I. Cantacuzino Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
700    1_
$a Zerr, Pawel $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Liebl, Andrea $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Mancuso, Rossella $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Tomcik, Michal $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany. Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Sumova, Barbora $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany. Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Dees, Clara $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Chen, Chih-Wei $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Wohlfahrt, Thomas $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Mallano, Tatjana $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Distler, Alfiya $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Ramming, Andreas $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Gelse, Kolja $u Department of Trauma Surgery, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Mihai, Carina $u Department of Internal Medicine and Rheumatology, Dr. I. Cantacuzino Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
700    1_
$a Distler, Oliver $u Research of Systemic Autoimmune Diseases, Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland.
700    1_
$a Schett, Georg $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Distler, Jörg H W $u Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
773    0_
$w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 76, č. 1 (2017), s. 244-251
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27113414 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170720124119 $b ABA008
999    __
$a ok $b bmc $g 1239720 $s 984952
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 76 $c 1 $d 244-251 $e 20160425 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Archiving options